Drug Profile


Alternative Names: IFN-tau; Tauferon; trophoblast interferon-tau; Trophoblastin

Latest Information Update: 10 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pepgen Corporation
  • Class Antivirals; Interferons
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections; Multiple sclerosis

Most Recent Events

  • 26 May 2006 This compound is still in active development
  • 30 Jun 2003 Phase-II clinical trials in Multiple sclerosis in USA (PO)
  • 21 Jun 2001 A study in patients with relapsing-remitting multiple sclerosis has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top